Field & Main Bank Grows Position in Eli Lilly and Company (NYSE:LLY)

Field & Main Bank grew its position in Eli Lilly and Company (NYSE:LLY) by 0.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,172 shares of the company’s stock after purchasing an additional 27 shares during the quarter. Eli Lilly and Company makes up approximately 2.6% of Field & Main Bank’s portfolio, making the stock its 5th largest holding. Field & Main Bank’s holdings in Eli Lilly and Company were worth $7,240,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Oxbow Advisors LLC raised its position in shares of Eli Lilly and Company by 4.4% in the third quarter. Oxbow Advisors LLC now owns 1,092 shares of the company’s stock valued at $967,000 after purchasing an additional 46 shares during the period. Objective Capital Management LLC bought a new position in shares of Eli Lilly and Company in the third quarter valued at approximately $298,000. SilverOak Wealth Management LLC raised its position in shares of Eli Lilly and Company by 59.1% in the third quarter. SilverOak Wealth Management LLC now owns 627 shares of the company’s stock valued at $555,000 after purchasing an additional 233 shares during the period. Lindbrook Capital LLC raised its position in shares of Eli Lilly and Company by 2.4% in the third quarter. Lindbrook Capital LLC now owns 6,849 shares of the company’s stock valued at $6,067,000 after purchasing an additional 163 shares during the period. Finally, Bridges Investment Management Inc. raised its position in shares of Eli Lilly and Company by 4.3% in the third quarter. Bridges Investment Management Inc. now owns 11,845 shares of the company’s stock valued at $10,494,000 after purchasing an additional 484 shares during the period. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LLY. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Barclays dropped their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Finally, Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,008.41.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Up 4.3 %

Shares of NYSE LLY opened at $831.54 on Friday. The firm’s 50-day simple moving average is $896.31 and its 200 day simple moving average is $867.53. The company has a market cap of $789.40 billion, a price-to-earnings ratio of 89.90, a price-to-earnings-growth ratio of 2.94 and a beta of 0.43. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the company earned $0.10 EPS. On average, research analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.63%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.